新型化合物已进入三阴性乳腺癌（TNBC）治疗方案，即免疫检查点抑制剂（ICIs）、PARP抑制剂和抗体药物偶联物（ADC）。通过使用联合治疗和加入新化合物可以增强治疗效果的优化。在这篇综述中，我们讨论了正在开发的治疗 TNBC 的联合疗法。近年来新药的开发推动了针对 TNBC 异质性和改善预后的新型联合疗法的研究。 ICI、ADC、酪氨酸激酶抑制剂 (TKI) 和 PARP 抑制剂已成为这一新领域的主要参与者，而新型细胞内通路抑制剂或癌症疫苗等其他化合物也引起了越来越多的兴趣。 TNBC 的未来以组合方法概述，并基于新的癌症靶标，包括许多无需化疗的治疗。大量 TNBC 疗法要么被证明临床无效，要么因安全性不可接受而受到影响。然而，其他一些药物已经提供了有希望的结果，目前正处于后期临床试验中，而一些药物近年来实际上改变了临床实践。随着越来越多的新型选择性药物的出现，以协同概念为重点的联合策略在未来是完全有必要的。

Novel compounds have entered the triple-negative breast cancer (TNBC) treatment algorithm, namely immune checkpoints inhibitors (ICIs), PARP inhibitors and antibody-drug conjugates (ADCs). The optimization of treatment efficacy can be enhanced with the use of combination treatments, and the incorporation of novel compounds. In this review, we discuss the combination treatments under development for the treatment of TNBC.The development of new drugs occurring in recent years has boosted the research for novel combinations to target TNBC heterogeneity and improve outcomes. ICIs, ADCs, tyrosine kinase inhibitors (TKIs), and PARP inhibitors have emerged as leading players in this new landscape, while other compounds like novel intracellular pathways inhibitors or cancer vaccines are drawing more and more interest. The future of TNBC is outlined in combination approaches, and based on new cancer targets, including many chemotherapy-free treatments.A large number of TNBC therapies have either proved clinically ineffective or weighted by unacceptable safety profiles. Others, however, have provided promising results and are currently in late-stage clinical trials, while a few have actually changed clinical practice in recent years. As novel, more and more selective drugs come up, combination strategies focusing the concept of synergy are fully warranted for the future.